ASH 2015 | The future of multiple myeloma treatment
Gareth Morgan
• 26 Feb 2016
Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR discusses the future of multiple myeloma (MM) treatment. Dr Morgan believes that newly diagnosed patients will receive a drug combination that will be able to overcome the intra-clonal heterogeneity and eradicate high-risk sub-clones that lead to early relapse. To achieve this, we need to have novel end-points that can be applied early in the disease process that are surrogates for long-term outcome and perhaps minimum residual disease detachment is one of those surrogates.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.
